<DOC>
	<DOCNO>NCT02217514</DOCNO>
	<brief_summary>Evaluation long-term ( 48 h ) short-term ( 1 h ) effect BI 44370 BS pharmacokinetics midazolam marker possible inhibition CYP 3A4 ; safety tolerability .</brief_summary>
	<brief_title>Effects BI 44370 TA Orally Applied Tablets Pharmacokinetics Orally Administered Midazolam Solution Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥21 Age ≤50 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation . Any finding medical examination ( include Blood Pressure ( BP ) , Pulse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within 30 day prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 470 m ) ; A history additional risk factor Torsade de Pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For Male Subjects : Not willing use adequate contraception ( condom use plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ( IUD ) ) whole study period time first intake study drug three month last intake For Female Subjects : Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilisation , intrauterine pessary ( IUP ) , oral contraceptive ) Inability maintain adequate contraception whole study period whole study period time first intake study drug one month last intake</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>